Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti‐transcriptional intermediary factor 1‐γ antibody‐positive dermatomyositis: A case report

Kim, Yoonjoo; Park, Dongil; Choi, Song-Yi; Chung, Chaeuk

doi:10.1111/1759-7714.14609

Cited by 7 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T cells and macrophages, by binding to these adhesion molecules through their surface integrin, traverse endothelial cells and infiltrate muscle tissue, releasing various proinflammatory factors, including TNF-α, thereby fostering tissue damage. Consequently, in tissue pathology, we commonly observe the infiltration of inflammatory cells surrounding capillaries, capillary necrosis, and muscle bundle rupture or atrophy ( 4 , 12 – 14 ). In summary, cancer can trigger autoimmune diseases via cross-immune reactions between antibodies and structurally analogous antigenic components found in muscle and skin tissues.…”

Section: Discussionmentioning

confidence: 99%

Small cell lung cancer with dermatomyositis: a case report

Guan,

Qiu,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Dermatomyositis represents an autoimmune disorder characterized by notable skin and muscular manifestations. The annual incidence of dermatomyositis stands at approximately (5~10)/1 million individuals. Notably, patients with malignant tumors exhibit an elevated risk of developing dermatomyositis compared to the general population. However, in cases where dermatomyositis co-occurs with malignancy, the efficacy of hormone therapy alone tends to be suboptimal. Moreover, reports addressing the correlation between tumor treatment and the management of dermatomyositis are scarce. A 60-year-old male patient presented with dermatomyositis, initially manifesting through symptoms such as rash, muscle weakness, and dysphagia. Despite undergoing standard hormone therapy, there was no discernible improvement in the dermatomyositis symptoms. Considering the patient’s concomitant troublesome cough, further investigations were conducted, including CT, PET-CT, and pathological biopsy. These assessments confirmed the diagnosis of limited-stage small cell lung cancer (T1cN3M0 IIIB). Notably, in this patient, dermatomyositis was suspected to be a paraneoplastic syndrome associated with small cell lung cancer. Standard chemotherapy and radiotherapy were employed to treat the small cell lung cancer, resulting in partial remission after two treatment cycles. As the malignancy regressed, a notable improvement in dermatomyositis symptoms was observed, subsequently leading to a gradual reduction in the prescribed hormone dosage. In conclusion, we present a comprehensive case study of dermatomyositis as a paraneoplastic syndrome throughout the treatment process. The response to tumor therapy coincided with the amelioration of dermatomyositis symptoms. Therefore, diligent malignancy screening is imperative for patients diagnosed with dermatomyositis.

show abstract

Section: Discussionmentioning

confidence: 99%

Small cell lung cancer with dermatomyositis: a case report

Guan,

Qiu,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Treatment of lung cancer has been developing rapidly, and many effective treatments, such as targeted therapy, immunotherapy, and antibody-drug conjugates, can be used in a clinical setting [1,35,36]. Next-generation sequencing is a very popular method of identifying optimal drugs for patients with lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Cryobiopsy: A Breakthrough Strategy for Clinical Utilization of Lung Cancer Organoids

Park

Lee

Kim

et al. 2023

Cells

Self Cite

View full text Add to dashboard Cite

One major challenge associated with lung cancer organoids (LCOs) is their predominant derivation from surgical specimens of patients with early-stage lung cancer. However, patients with advanced lung cancer, who are in need of chemotherapy, often cannot undergo surgery. Therefore, there is an urgent need to successfully generate LCOs from biopsy specimens. Conventional lung biopsy techniques, such as transthoracic needle biopsy and forceps biopsy, only yield small amounts of lung tissue, resulting in a low success rate for culturing LCOs from biopsy samples. Furthermore, potential complications, like bleeding and pneumothorax, make it difficult to obtain sufficient tissue. Another critical issue is the overgrowth of normal lung cells in later passages of LCO culture, and the optimal culture conditions for LCOs are yet to be determined. To address these limitations, we attempted to create LCOs from cryobiopsy specimens obtained from patients with lung cancer (n = 113). Overall, the initial success rate of establishing LCOs from cryobiopsy samples was 40.7% (n = 46). Transbronchial cryobiopsy enables the retrieval of significantly larger amounts of lung tissue than bronchoscopic forceps biopsy. Additionally, cryobiopsy can be employed for peripheral lesions, and it is aided via radial endobronchial ultrasonography. This study significantly improved the success rate of LCO culture and demonstrated that the LCOs retained characteristics that resembled the primary tumors. Single-cell RNA sequencing confirmed high cancer cell purity in early passages of LCOs derived from patients with advanced lung cancer. Furthermore, the three-dimensional structure and intracellular components of LCOs were characterized using three-dimensional holotomography. Finally, drug screening was performed using a specialized micropillar culture system with cryobiopsy-derived LCOs. LCOs derived from cryobiopsy specimens offer a promising solution to the critical limitations of conventional LCOs. Cryobiopsy can be applied to patients with lung cancer at all stages, including those with peripheral lesions, and can provide sufficient cells for LCO generation. Therefore, we anticipate that cryobiopsy will serve as a breakthrough strategy for the clinical application of LCOs in all stages of lung cancer.

show abstract

“…The link between DM and cancer has been well established in the literature, and while the specific types vary between populations, lung cancer is frequently observed [ 5 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ]. The majority of cancer cases occur within 1 year prior to or post DM diagnosis, and this was observed in our data set, with all but 1 patient having both diagnoses in this timeframe.…”

Section: Discussionmentioning

confidence: 99%

“…Current theories include the fact that immunosuppressive treatment for DM may allow for cancer emergence; cancer may bring about immunological changes that lead to DM; certain DM-associated autoantibodies may play a role in cancer promotion/progression; once a diagnosis of DM or lung cancer is made, the patient is under increased surveillance resulting in the diagnosis of the second disease [ 27 ]. Malignancy is a leading cause of death in DM patients, with the 5-year survival rate of DM patients being between 60–90.1%, and the 5-year survival rate for DM patients with cancer being between 10–56% [ 30 , 31 , 32 ]. Interestingly, to the best of our knowledge, there is only a single published case of DM that resulted in disease resolution following treatment with immunotherapy [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Dermatomyositis Associated with Lung Cancer: A Brief Review of the Current Literature and Retrospective Single Institution Experience

Shalata

Zolnoorian

Meirovitz

et al. 2022

Life

View full text Add to dashboard Cite

Dermatomyositis is a rare inflammatory myopathy that is often related to lung cancer. In this retrospective observational study, we analyzed data from patients diagnosed with lung cancer at Soroka University Medical Center between January 2017 and July 2021. A total of 689 patients with lung cancer were included in this study, 97 of whom had small cell lung cancer and 592 had non-small cell lung cancer. We identified a single patient (60-year-old female) who presented with signs and symptoms of dermatomyositis, which was later confirmed to be associated with lung cancer as a paraneoplastic syndrome. Both our study and a recent review of the literature illustrate the temporal link between dermatomyositis and lung cancer, as well as reinforce the need for heightened cancer screenings in DM patients.

show abstract

Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti‐transcriptional intermediary factor 1‐γ antibody‐positive dermatomyositis: A case report

Cited by 7 publications

References 20 publications

Small cell lung cancer with dermatomyositis: a case report

Small cell lung cancer with dermatomyositis: a case report

Cryobiopsy: A Breakthrough Strategy for Clinical Utilization of Lung Cancer Organoids

Dermatomyositis Associated with Lung Cancer: A Brief Review of the Current Literature and Retrospective Single Institution Experience

Contact Info

Product

Resources

About